Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
|
|
BIOTRICITY INC. (BTCY)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/17/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/04/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 07/20/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
8-K
| Quarterly results|
Docs:
|
"Biotricity Reports Business Update, Financial Results for Q4 and Full Year FY23; Company Posts Robust Revenue Growth, Overall Higher Margins, with Lower SG&A Driving Clear Path to Positive Cash Flow",
"Biotricity Announces Reverse Stock Split REDWOOD CITY, CA / ACCESSWIRE / June 30, 2023 / Biotricity Holdings, Inc. , a medical diagnostic and consumer healthcare technology company, today it will effect a reverse stock split of its common stock. Biotricity expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on July 3, 2023." |
|
| 06/29/2023 |
10-K
| Annual Report for the period ended March 31, 2023 |
| 05/18/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...|
Docs:
|
"SUBSCRIPTION AGREEMENT",
"CONVERTIBLE PROMISSORY NOTE THIS NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS. BIOTRICITY INC. CONVERTIBLE PROMISSORY NOTE",
"WARRANT THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED , OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, WHICH OPINION SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. No. [__] Issue Date: [DATE] Biotricity Inc. Common Stock Purchase Warrant _________________ THIS CERTIFIES THAT, for value received, [_____] is entitled to subscribe for and purchas...",
"Cover Page Interactive Data File (embedded within the Inline XBRL document)" |
|
| 04/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/22/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/15/2023 |
4
| Rosa David A (Director) has filed a Form 4 on BIOTRICITY INC.|
Txns:
| Granted 75,930 options to buy
@ $1.94, valued at
$147.3k
|
|
| 03/14/2023 |
4
| Al-Siddiq Waqaas (President, CEO and Chairman) has filed a Form 4 on BIOTRICITY INC.|
Txns:
| Granted 350,000 options to buy
@ $1.25, valued at
$437.5k
Granted 350,000 options to buy
@ $1.75, valued at
$612.5k
Granted 1,000,000 options to buy
@ $0.81, valued at
$810k
|
|
| 03/13/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/13/2023 |
4
| Ayanoglou John (CFO) has filed a Form 4 on BIOTRICITY INC.|
Txns:
| Granted 50,000 warrants
@ $0.73, valued at
$36.5k
Granted 50,000 warrants
@ $0.73, valued at
$36.5k
Granted 50,000 warrants
@ $0.73, valued at
$36.5k
Granted 50,000 warrants
@ $0.73, valued at
$36.5k
Granted 50,000 warrants
@ $0.48, valued at
$24k
Granted 50,000 warrants
@ $0.91, valued at
$45.5k
Granted 50,000 warrants
@ $0.66, valued at
$33k
Granted 50,000 warrants
@ $0.58, valued at
$29k
Granted 50,000 warrants
@ $0.63, valued at
$31.5k
Granted 50,000 warrants
@ $0.974, valued at
$48.7k
Granted 50,000 warrants
@ $1.367, valued at
$68.4k
|
|
| 03/02/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 02/14/2023 |
10-Q
| Quarterly Report for the period ended December 31, 2022 |
| 01/27/2023 |
8-K
| Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ... |
| 01/20/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 11/18/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 09/09/2022 |
4
| Rosa David A (Director) has filed a Form 4 on BIOTRICITY INC.|
Txns:
| Granted 31,106 options to buy
@ $2.4, valued at
$74.7k
|
|
| 09/01/2022 |
3
| White Chester P (Director) has filed a Form 3 on BIOTRICITY INC. |
| 08/16/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/11/2022 |
8-K
| Quarterly results |
| 07/15/2022 |
8-K
| Quarterly results |
| 07/14/2022 |
10-K
| Annual Report for the period ended March 31, 2022 |
| 06/29/2022 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 05/16/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 05/06/2022 |
8-K
| Quarterly results |
| 04/27/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 04/26/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/14/2022 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 04/08/2022 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 03/22/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 03/22/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
|
|
|